1
|
Molecular modelling studies for 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as anticancer agents. MEDICINE IN DRUG DISCOVERY 2019. [DOI: 10.1016/j.medidd.2019.100008] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
2
|
El Bakali J, Muccioli GG, Body-Malapel M, Djouina M, Klupsch F, Ghinet A, Barczyk A, Renault N, Chavatte P, Desreumaux P, Lambert DM, Millet R. Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis. ACS Med Chem Lett 2015; 6:198-203. [PMID: 25699149 DOI: 10.1021/ml500439x] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 12/04/2014] [Indexed: 12/23/2022] Open
Abstract
The CB2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation. Following on from the promising activity of a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide, we developed constrained analogues based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold, with improved affinity for the hCB2 receptor and had very high selectivity over the hCB1 receptor. Importantly, the lead of this series (26, hCB2: K i = 0.39 nM, hCB1: K i > 3000 nM) was found to protect mice against experimental colitis after oral administration.
Collapse
Affiliation(s)
- Jamal El Bakali
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| | - Giulio G. Muccioli
- Unité
de Chimie Pharmaceutique et de Radiopharmacie, Louvain Drug Research
Institute, Université catholique de Louvain, 73 avenue
E. Mounier UCL-CMFA (7340), B-1200 Bruxelles, Belgium
| | - Mathilde Body-Malapel
- Digestive inflammatory diseases: pathophysiology and development of therapeutic targets. U995 INSERM, Université Lille Nord de France, IFR 114, Amphis J & K, Boulevard du Professeur J. Leclercq, 59045 Lille Cedex, France
| | - Madjid Djouina
- Digestive inflammatory diseases: pathophysiology and development of therapeutic targets. U995 INSERM, Université Lille Nord de France, IFR 114, Amphis J & K, Boulevard du Professeur J. Leclercq, 59045 Lille Cedex, France
| | - Frédérique Klupsch
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| | - Alina Ghinet
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| | - Amélie Barczyk
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| | - Nicolas Renault
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| | - Philippe Chavatte
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| | - Pierre Desreumaux
- Digestive inflammatory diseases: pathophysiology and development of therapeutic targets. U995 INSERM, Université Lille Nord de France, IFR 114, Amphis J & K, Boulevard du Professeur J. Leclercq, 59045 Lille Cedex, France
| | - Didier M. Lambert
- Unité
de Chimie Pharmaceutique et de Radiopharmacie, Louvain Drug Research
Institute, Université catholique de Louvain, 73 avenue
E. Mounier UCL-CMFA (7340), B-1200 Bruxelles, Belgium
| | - Régis Millet
- Institut
de Chimie Pharmaceutique Albert Lespagnol, Université de Lille Nord de France, E.A 4481, IFR 114, 3 rue du Pr. Laguesse, B.P.
83, F-59006 Lille
Cedex, France
| |
Collapse
|
3
|
Calpain-1 inhibitors for selective treatment of rheumatoid arthritis: what is the future? Future Med Chem 2013; 5:2057-74. [DOI: 10.4155/fmc.13.172] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Effective small-molecule treatment of inflammatory diseases remains an unmet need in medicine. Current treatments are either limited in effectiveness or invasive. The latest biologics prevent influx of inflammatory cells to damaged tissue. Calpain-1 is a calcium-activated cysteine protease that plays an important role in neutrophil motility. It is, therefore, a potential target for intervention in inflammatory disease. Many inhibitors of calpains have been developed but most are unselective and so unsuitable for drug use. However, recent series of α-mercaptoacrylate inhibitors target regulatory domains of calpain-1 and are much more specific. These compounds are effective in impairing the cell spreading mechanism of neutrophils in vitro and raise the possibility of treating rheumatoid arthritis with a pill; however, challenges still remain. Improved bioavailability is needed and solution of their precise mode of action should prompt the development of specific calpain-1 screens for novel classes of inhibitors.
Collapse
|
4
|
Li S, Jiang R, Qin M, Liu H, Zhang G, Gong P. Synthesis and Antitumor Activity of Novel 4-(2-Fluorophenoxy)quinoline Derivatives Bearing the 4-Oxo-1,4-dihydroquinoline-3-carboxamide Moiety. Arch Pharm (Weinheim) 2013; 346:521-33. [DOI: 10.1002/ardp.201300029] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Revised: 04/20/2013] [Accepted: 04/26/2013] [Indexed: 11/07/2022]
Affiliation(s)
- Sai Li
- Key Laboratary of Original New Drugs Design and Discovery of Ministry of Education; Shenyang Pharmaceutical University; Shenyang, P. R. China
| | - Rui Jiang
- Key Laboratary of Original New Drugs Design and Discovery of Ministry of Education; Shenyang Pharmaceutical University; Shenyang, P. R. China
| | - Mingze Qin
- Key Laboratary of Original New Drugs Design and Discovery of Ministry of Education; Shenyang Pharmaceutical University; Shenyang, P. R. China
| | - Haicheng Liu
- Key Laboratary of Original New Drugs Design and Discovery of Ministry of Education; Shenyang Pharmaceutical University; Shenyang, P. R. China
| | - Guangyan Zhang
- Key Laboratary of Original New Drugs Design and Discovery of Ministry of Education; Shenyang Pharmaceutical University; Shenyang, P. R. China
| | - Ping Gong
- Key Laboratary of Original New Drugs Design and Discovery of Ministry of Education; Shenyang Pharmaceutical University; Shenyang, P. R. China
| |
Collapse
|
5
|
Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors. Bioorg Med Chem 2013; 21:2843-55. [PMID: 23628470 DOI: 10.1016/j.bmc.2013.04.013] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2013] [Revised: 04/01/2013] [Accepted: 04/04/2013] [Indexed: 12/24/2022]
Abstract
A series of novel 4-(2-fluorophenoxy)quinoline derivatives containing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and six typical cancer cell lines (A549, H460, HT-29, MKN-45, U87MG and SMMC-7721). All the prepared compounds showed moderate to excellent antiproliferative activity, and the analysis of their structure-activity relationships indicated that 2-chloro or 2-trifluoromethyl substituted phenyl group on the 1-position of cinnoline ring was more favorable for antitumor activity. In this study, a promising compound 33, with a c-Met IC50 value of 0.59 nM, was identified as a multitargeted receptor tyrosine kinase inhibitor.
Collapse
|
6
|
Lee EY, Jang IH, Shin MJ, Cho HJ, Kim JS, Eom JE, Kwon YJ, Na YH. Chalcones as Novel Non-peptidic μ-Calpain Inhibitors. B KOREAN CHEM SOC 2011. [DOI: 10.5012/bkcs.2011.32.9.3459] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
7
|
Abstract
The calpains are a conserved family of cysteine proteinases that catalyse the controlled proteolysis of many specific substrates. Calpain activity is implicated in several fundamental physiological processes, including cytoskeletal remodelling, cellular signalling, apoptosis and cell survival. Calpain expression is altered during tumorigenesis, and the proteolysis of numerous substrates, such as inhibitors of nuclear factor-κB (IκB), focal adhesion proteins (including, focal adhesion kinase and talin) and proto-oncogenes (for example, MYC), has been implicated in tumour pathogenesis. Recent evidence indicates that the increased expression of certain family members might influence the response to cancer therapies, providing justification for the development of novel calpain inhibitors.
Collapse
Affiliation(s)
- Sarah J Storr
- University of Nottingham, School of Molecular Medical Sciences, Nottingham NG5 1PB, UK
| | | | | | | | | |
Collapse
|
8
|
Kang DH, Jun KY, Lee JP, Pak CS, Na Y, Kwon Y. Identification of 3-Acetyl-2-aminoquinolin-4-one as a Novel, Nonpeptidic Scaffold for Specific Calpain Inhibitory Activity. J Med Chem 2009; 52:3093-7. [DOI: 10.1021/jm8014734] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Da-Hye Kang
- College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea, Department of Chemistry, Chungnam National University, Daejeon 305-764, Korea, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea, College of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk 712-702, Korea
| | - Kyu-Yeon Jun
- College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea, Department of Chemistry, Chungnam National University, Daejeon 305-764, Korea, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea, College of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk 712-702, Korea
| | - Jin Pyo Lee
- College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea, Department of Chemistry, Chungnam National University, Daejeon 305-764, Korea, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea, College of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk 712-702, Korea
| | - Chwang Siek Pak
- College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea, Department of Chemistry, Chungnam National University, Daejeon 305-764, Korea, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea, College of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk 712-702, Korea
| | - Younghwa Na
- College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea, Department of Chemistry, Chungnam National University, Daejeon 305-764, Korea, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea, College of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk 712-702, Korea
| | - Youngjoo Kwon
- College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea, Department of Chemistry, Chungnam National University, Daejeon 305-764, Korea, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea, College of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk 712-702, Korea
| |
Collapse
|
9
|
Guttmann R. Recent developments in the therapeutic targeting of calpains in neurodegeneration. Expert Opin Ther Pat 2007. [DOI: 10.1517/13543776.17.10.1203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
10
|
Guillonneau C, Nault A, Raimbaud E, Léonce S, Kraus-Berthier L, Pierré A, Goldstein S. Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues. Bioorg Med Chem 2005; 13:175-84. [PMID: 15582462 DOI: 10.1016/j.bmc.2004.09.047] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2004] [Accepted: 09/24/2004] [Indexed: 11/18/2022]
Abstract
The present study describes the synthesis and pharmacological profiles of new olivacine related compounds, possessing a modified D ring. The impact of this modification has been evaluated with respect to the cytotoxic and in vivo antitumoral effects of these molecules and in comparison with parent S 16020-2 previously prepared and investigated in our laboratory. The D ring size and number of nitrogen atoms as well as the position of the aminoalkyl substituent have a profound impact on the cytotoxic and antitumoral profiles. Thus out of the prepared pyrazinocarbazole compounds, 2 is devoid of any substantial cytotoxic and antitumoral activities while the pyrimidocarbazole 3 has a similar profile compared to 1 (S 16020-2). L1210 and P388 in vivo antitumoral effects are lost for both imidazocarbazoles 4 and 5, but the former conserves an in vivo antitumoral effect on B16 melanoma, this effect being the largest in the series. Structural similarities and differences amongst the studied compounds could be evidenced by calculation of global properties such as molecular electrostatic potentials (MEP maps) and partition coefficients (logP), thus adding information on the impact of chemical changes on these two parameters known to influence biological behavior.
Collapse
Affiliation(s)
- Claude Guillonneau
- Servier, Division Chimie A, 11 rue des Moulineaux, 92150 Suresnes, France
| | | | | | | | | | | | | |
Collapse
|
11
|
Athanasellis G, Gavrielatos E, Igglessi-Markopoulou O, Markopoulos J. Novel ‘quinolone’ metal complexes: Synthesis and spectroscopic studies of mg(II), zn(II) and ba(II) complexes with N-methyl (or NH)-3-acetyl-4-hydroxy quinolin-2-one ligands. J Heterocycl Chem 2003. [DOI: 10.1002/jhet.5570400413] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
12
|
Affiliation(s)
- D L Mykles
- Department of Biology, Cell and Molecular Biology Program and Molecular, Cellular, and Integration Neurosciences Program, Colorado State University, Fort Collins, Colorado 80523, USA
| |
Collapse
|
13
|
Chatterjee S, Iqbal M, Kauer JC, Mallamo JP, Senadhi S, Mallya S, Bozyczko-Coyne D, Siman R. Xanthene derived potent nonpeptidic inhibitors of recombinant human calpain I. Bioorg Med Chem Lett 1996. [DOI: 10.1016/s0960-894x(96)00286-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Wang KK, Yuen PW. Development and therapeutic potential of calpain inhibitors. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1996; 37:117-52. [PMID: 8891101 DOI: 10.1016/s1054-3589(08)60949-7] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- K K Wang
- Department of Neuroscience Therapeutics Parke-Davis Pharmaceutical Research Warner-Lambert Company, Ann Arbor, Michigan 48105, USA
| | | |
Collapse
|